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The Glutamate Release Inhibitor Riluzole
Decreases Migration, Invasion, and Proliferation
of Melanoma Cells
Maithao N. Le1,4, Joseph L.-K. Chan1,2,4, Stephen A. Rosenberg2, Adam S. Nabatian2, Kim T. Merrigan2,3,
Karine A. Cohen-Solal2,3 and James S. Goydos1,2
The goal of this study was to examine the effects of metabotropic glutamate receptor-1 (GRM1) blockade on
melanoma anchorage-independent growth and invasion. We performed colony and invasion assays using
GRM1-expressing melanoma lines and the GRM1-negative UACC930 line. Using the glutamate-release inhibitor
Riluzole or the non-competitive GRM1 antagonist BAY 36-7620 we were able to induce considerable inhibition
of colony formation and invasion in GRM1-expressing melanoma lines. Neither pharmacological agent induced
significant reduction in colony formation or invasion in the GRM1-negative melanoma line, UACC930.
Additionally we assessed the efficacy of these inhibitors to inhibit the growth of fresh melanoma tumor samples
cultured on a 74-mm nylon mesh. Both Riluzole and BAY 36-7620 significantly inhibited tumor cell growth into
the interstitial spaces of the mesh. When repeated with normal mole samples both inhibitors were much less
effective in preventing the outgrowth of cells. These experiments show that a specific antagonist of GRM1 (BAY
36-7620) or an inhibitor of glutamate release (Riluzole) can significantly suppress melanoma migration, invasion
and colony formation as well as inhibit the proliferation of fresh melanoma cells. These findings, added to our
previous work, strengthen the case that GRM1 is a valid therapeutic target in patients with melanoma.
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INTRODUCTION
The incidence of melanoma continues to rise, with almost
70,000 cases of invasive melanoma reported in the United
States in 2008 (Jemal et al., 2008). When found early
melanoma can usually be successfully treated with surgical
excision (Garbe and Eigentler, 2007; Dummer et al., 2009).
However, metastatic disease is refractory to current therapies
and has a very poor prognosis (Bhatia et al., 2009; Mansfield
and Markovic, 2009; Mouawad et al., 2010). Aberrant
mitogen-activated protein kinase (MAPK), as well as other
specific signal transduction pathways, has been implicated in
melanoma formation, local progression, and distant meta-
static spread. Therapies targeting specific components of
these pathways have been developed and many are currently
in human trials. However, early results from the use of single
agents targeting specific signaling molecules such as N-RAS,
B-RAF, MEK, and others have been disappointing (Flaherty,
2008), although more specific inhibitors of mutated B-RAF
have shown some success in early trials (Smalley et al.,
2009). It is now generally believed that multiple pathways,
many with redundant downstream effects, are dysregulated in
melanoma and therapies that target multiple pathways at
once will probably be needed if these therapies are going to
be effective.
Recently, our group described a heretofore-unknown
component of melanoma pathogenesis. A transgenic murine
model of melanoma was developed by ectopic expression of
metabotropic glutamate receptor-1 (murine GRM1) in mela-
nocytes (Pollock et al., 2003; Marin et al., 2006; Namkoong
et al., 2007). These mice spontaneously develop melanocytic
lesions indistinguishable from human melanoma. We have
expanded these original studies and have now shown that
over 60% of human melanomas express the human form of
this receptor, human GRM1, and that activation of this
receptor results in activation of the MAPK and phoshatidy-
linositol-3-kinase (PI3K)/AKT pathways in a B-RAF and
N-RAS-independent manner (Marin et al., 2006). In pre-
clinical studies we have shown that ectopic expression of
murine GRM1 in murine melanocytes is transforming and
that inhibition of human GRM1 signaling in vitro and in vivo
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results in cell-cycle arrest and subsequent apoptosis in human
melanoma. We have now translated our findings into the
clinic and have completed a phase-0 trial of Riluzole (2-
amino-6-trifluoromethoxybenzothiazole), an inhibitor of glu-
tamate signaling, in patients with stage-III and IV melanoma.
We found that administration of oral Riluzole resulted in
suppression of MAPK and PI3K/AKT pathway signaling, and
involution of tumor in 34% of patients (Yip et al., 2009). We
also found an increase in the number of apoptotic cells in
post-treatment tumor samples. We have now embarked on a
phase-II therapeutic trial of single-agent Riluzole in patients
with advanced melanoma and we have continued our pre-
clinical studies examining the effects of Riluzole therapy on
melanoma cells.
Our pre-clinical and early clinical experiments suggest
that blockade of glutamate signaling in GRM1-expressing
melanoma cells results in suppression of signaling through
the MAPK and PI3K/AKT pathways. However, we do not
know if the therapeutic effects we have observed in pre-
clinical and early clinical studies using GRM1 antagonists or
Riluzole are the result of inhibition of MAPK and PI3K/AKT
signaling. To help determine whether inhibition of signaling
through these pathways is responsible for the observed
therapeutic effects, we investigated whether treatment with
a non-competitive pharmacological antagonist of GRM1
signaling (BAY 36-7620) or the glutamate release inhibitor
Riluzole could attenuate aspects of the transformed pheno-
type of human melanoma cells attributed to MAPK and PI3K/
AKT activation (Hendrix et al., 2003; Hess et al., 2005).
Additionally, the agents Riluzole and BAY 36-7620 were
evaluated for their potential to inhibit the growth of fresh
melanoma tumor samples in an in vitro organotypic culture
system in anticipation of using this system to screen agents,
either alone or in combination, that could be used in future
in vivo experiments and clinical trials.
RESULTS
It was previously shown that inhibition of GRM1 signaling
with the glutamate release inhibitor Riluzole or the specific
non-competitive GRM1 antagonist BAY 36-7620 resulted in
decreased monolayer growth of human melanoma cell
lines (Namkoong et al., 2007). To extend our understanding
of the effects of GRM1 inhibition on melanocytic transforma-
tion we used these pharmacological agents to determine
their effect on the anchorage-independent growth of
various human melanoma cell lines. The cell lines used
were C8161(GRM1þ , B-Raf/N-Ras WT), HT144(GRM1þ , B-RafV600E),
SKMEL2(GRM1þ , N-RasQ61R), and UACC930(GRM1, B-RafV600E)
melanoma cell lines. These cell lines were chosen on the
basis of GRM1, BRAF, and NRAS status. Overall our results
show that inhibition of GRM1 function significantly reduces
colony formation in melanoma cells expressing GRM1 but
not in GRM1-negative UACC930 cells (Figure 1a). Treatment
with 25 mM Riluzole potently affected the colony formation of
C8161, inducing 80.5% inhibition (Figure 1b). Inhibition was
less pronounced in HT144 and SKMEL2 cells, with the
number of colonies reducing 34.9 and 39.9%, respectively
(Figure 1b). Riluzole treatment had minimal effect on the
GRM1-negative UACC930 cells, reducing anchorage-inde-
pendent growth only 10.5%. The non-competitive GRM1
antagonist BAY 36-7620 produced slightly less but similar
results, inducing 46.9, 25.8, and 30.9% inhibition of colony
formation in C8161, HT144, and SKMEL2 cells, respectively
(Figure 1b). BAY 36-7620 essentially had little to no effect on
the UACC930 cells. Our positive control, the MEK inhibitor
U0126, which has been shown to inhibit three-dimensional
growth and invasion in C8161 cells (Ge et al., 2002; Hess
et al., 2005), proved to be least effective pharmacological
inhibitor, having only a dramatic effect on SKMEL2 colony
formation.
In addition to decreasing the number of colonies formed,
Riluzole and BAY 36-7620 had a significant effect on the size
of the colonies that did form (Figure 1c). This effect was most
pronounced in C8161 as shown by the colony size
distribution curve (Figure 1c). Treatment of the cells with
Riluzole and BAY 36-7620 resulted in a size distribution
curve with an early tight peak as opposed to untreated cells
where there was a broad peak. The lower peak observed in
Riluzole relative to BAY 36-7620 is reflective of the reduced
number of colonies formed. The effect on the colony sizes in
HT144 and SKMEL2 were less pronounced as the curve peaks
are all at the same position. However, in HT144 there are
fewer large colonies in both Riluzole- and BAY 36-7620-
treated cells (Figure 1c). Whereas Riluzole also produced the
same effect in SKMEL2 cells, BAY 36-7620 did not. U0126,
which was effective in inhibiting SKMEL2 colony formation,
also suppressed the formation of large colonies in these cells.
Collectively our results show that Riluzole and BAY 36-7620
reduce both colony formation and colony size in C8161 cells.
In HT144 and SKMEL2 cells Riluzole and BAY 36-7620
reduce colony numbers. Whereas Riluzole prevented the
formation of large colonies in both cell lines, BAY 36-7620
was only effective in HT144 cells.
Another aspect of cellular transformation is the ability of
cells to invade through an extracellular matrix and migrate.
To determine whether inhibition of GRM1 signaling affects
the invasive potential of these melanoma cells, an in vitro
Boyden chamber invasion assay was performed (Figure 2a).
Riluzole was quite effective in suppressing the invasive
potential of C8161, HT144, and SKMEL2, reducing the
numbers of invaded cells 60.9, 59.7, and 65.2% (Figure 2b).
BAY 36-7620 was just as effective, inducing 55.8, 58.0, and
54.0% inhibition of invasion (Figure 2b). Neither pharmaco-
logical agent inhibited UACC930 invasion; in fact both
appeared to slightly increase invasion (Figure 1b). These
results were somewhat surprising as the levels of inhibition
between the GRM1þ cell lines were very similar and
inconsistent with the results observed in the colony formation
of these cells where the BRAF and NRAS mutants were less
affected by the treatments. Although invasion and anchorage-
independent growth are different aspects of the transformed
phenotype and thus may be differentially affected by GRM1
inhibition, they share many common pathways. To determine
whether this uniformity of inhibition was a unique phenom-
enon, we examined the invasive potential of several other
cell lines harboring BRAF- and NRAS-activating mutations
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when treated with Riluzole and BAY 36-7620. Similar levels
of inhibition were observed in all the cell lines tested (Figure
2b). With the exception of UACC930 Riluzole induced a
56.3–73.3% inhibition of invasion whereas BAY 36-7620
reduced invasion 42.4–68.9% in the cell lines tested. With
the exception of SKMEL5, U0126 was effective in attenuating
the invasive potential of all the cell lines, including
UACC930.
Invasion is a multifaceted phenomenon in which both
digestion of extracellular matrix proteins and cell motility, as
well as other events, are involved. Using our panel of cell
lines we next determined whether inhibition of GRM1
signaling attenuates the proteolytic breakdown of the
extracellular matrix. We first assessed if our inhibitors had
any effect on the activity of the urokinase-type plasminogen
activator (uPA). uPA is secreted from the cells in an inactive
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Figure 1. Riluzole and BAY 36-7620 inhibit the anchorage-independent growth of human melanoma cell lines. Soft agar colony assays were performed with
C8161 (5 104 cells), HT144 (1.5104 cells), SKMEL2 (1.5 104 cells), and UACC930 (5104 cells) in the presence of 25mM Riluzole, 50mM Bay 36-7620,
10mM U0126, or vehicle solvent (DMSO). Colony assays were fed with 200 ml of 10% FBS RPMI containing the appropriate inhibitors every 48 hours after the
initiation of the assay. Photomicrographs of three representative fields were taken after 14 days or 28 days in the case of UACC930 (a). The number of colonies
(b) and colony size (c) for each photomicrograph was determined using Image J and the sum totals were plotted. Histograms represent the average of three
independent experiments with the exception of UACC930 (two experiments). Magnification bar¼500 mm (a).
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form and binds to its receptor, UPAR, and becomes activated.
We postulated that potentially activated uPA remains bound
to uPA receptor and is not in the media. Under this
assumption we performed uPA assays with total protein
lysates isolated from cells treated with our inhibitors for
18 hours. Treatment of C8161 cells with Riluzole resulted in
27.5% decrease in activity. It was less effective in HT144 and
SKMEL2, reducing activity 12.9 and 17.3%. BAY 36-7620
was equally effective across the three cell lines, producing a
19.5–23.8% decrease in uPA activity. Riluzole and BAY
36-7620 were the least effective in UACC930 cells, reducing
activity 12.0 and 15.4%, respectively. U0126 appeared to be
the most effective, producing 24.3–37.5% reduction. Aside
from uPA, matrix metalloprotease-2 has also been shown to
be important in metastatic and invasive activity in melanoma;
however neither Riluzole nor BAY 36-7620 appeared to
affect matrix metalloprotease-2 (Supplementary Figure S1
online).
While our pharmacological agents did induce a slight
inhibition of uPA activity, the levels of inhibition did not
correlate with our invasion data. U0126, which was the least
effective in inhibiting invasion, induced the greatest amount
of inhibition of uPA activity. Clearly there was another
component of invasion being impacted by the inhibitors. The
MAP and PI3K/AKT pathways have been shown to be
important in both anchorage-independent growth and inva-
sion (Hess et al., 2005; Meier et al., 2005). It has also been
reported that GRM1 activation leads to upregulated signaling
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Figure 2. Glutamate blockade inhibits the invasive potential of human melanoma cell lines. Boyden chamber invasion assays were performed with
various human melanoma cell lines as described under Materials and Methods in the presence of 25 mM Riluzole, 50 mM BAY 36-7620, 10mM U0126, or vehicle
solvent (DMSO). 1 105 cells were used for the assays, with the exception of C8161 and A2058 cell lines (2104 cells). Cells were allowed to invade 18hours
with the exception of UACC930 (48 hours). For UACC930 a fluid renewal containing inhibitors was performed at 24 hours. The invaded cells were fixed,
stained, and three representative fields were photomicrographed (a). The relative levels of invasion for each cell line and treatment was determined using Image J
and the results were plotted (b). The histogram represents the average of three independent experiments. For uPA activity assays (c), 5 105 cells were
plated into four parallel wells in a six-well plate and allowed to recover O/N. They were then treated with the indicated inhibitors in serum-free RPMI-1640
medium for 6 hours and then replaced with fresh serum-free medium containing the inhibitors and returned to the incubator for an additional 12 hours.
The medium was then collected and protein lysates were prepared as indicated under Materials and Methods. Using 20 mg of total cell lysate, an
in vitro uPA activity assay was performed according to the manufacturer’s instructions (c). Bar¼500 mm (a).
www.jidonline.org 2243
MN Le et al.
Riluzole Attenuates Melanoma Cell Transformation
through these pathways (Marin et al., 2006). To assess the
effects of GRM1 signaling inhibition on these pathways we
performed western blot analysis. As Riluzole appears to be
more effective than BAY 36-7620, particularly in the
inhibition of colony formation, we restricted our analysis to
the effects of Riluzole. We performed a kinetic analysis where
C8161 cells were treated with 25 mM Riluzole and total
protein lysates were prepared every 3 hours after treatment.
These lysates were then western blotted for phospho-AKT and
phospho-ERK to determine at which point after Riluzole
treatment we would see downregulation of AKT and
extracellular signal-regulated kinase (ERK)1/2 phosphoryla-
tion (data not shown). It was determined that we see
significant reduction of phosphorylation between 6
and 9 hours. Using an 8-hour treatment time we
proceeded to assess the effects of Riluzole in the cell lines
(Figure 3a and b).
C8161 and SKMEL2 cells, upon treatment with Riluzole
for 8 hours, showed 80.4 and 80.1% reduction in pAKTT308
levels (Figure 3a and b). It was much less effective in HT144
cells, only inducing a 30.2% decrease. In UACC930 cells
Riluzole treatment actually induced a greater than twofold
increase in phosphorylation (Figure 3a and b). Examination of
the AKTS473 site showed that Riluzole was equally effective in
inhibiting phosphorylation in C8161 cells but somewhat less
effective in HT144 and SKMEL2 cells, 77.5 versus 25.3 and
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Figure 3. Treatment of human melanoma cells with Riluzole inhibits AKT and ERK phosphorylation. C8161, HT144, SKMEL2, and UACC930 human
melanoma cell lines were plated at a density of 8105 cell/60-mm dish and allowed to recover O/N. The next day the cells were treated 25 mM Riluzole or
vehicle solvent (DMSO) for 8 hours after which total cell lysates (TCLs) were prepared, protein levels were determined, and 10 mg of TCL was resolve by SDS-
PAGE (a). Proteins were electroblotted onto polyvinylidene difluoride membranes and probed with the indicated primary and the corresponding secondary
antibodies. Chemiluminescence detection was performed using ECL-plus or ECL-Advance and exposure to X-ray film. The representative of two (UACC930) or
three independent experiments is shown (a). Densitometric analysis was performed using Image J to determine protein phosphorylation and expression levels.
The normalized protein phosphorylation levels were then plotted (b). The histogram represents the average of two (UACC930) or three independent experiments.
A parallel set of cells were treated as above; TCLs were prepared at 18 hours after treatment and processed as above (c).
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59.7% (Figure 3a and b). As with AKTT308, it appears that
Riluzole induced greater than twofold increase in phosphory-
lation in UACC930 cells. A similar pattern was observed
when we assessed the phospho-ERK-1/2 levels. There was
37.8, 14.9, and 41.1% decrease in phosphorylation in
C8161, HT144, and SKMEL2 cells, respectively. As with
phospho-AKT, Riluzole appears to have the opposite effect on
UACC930 cells, inducing 21.9% increase in phosphorylation
of ERK-1/2.
In cancer cell systems there are feedback mechanisms that
often diminish the negative effects induced by inhibitors
resulting in a reactivation of the affected signal transduction
pathways. To determine whether the observed downregula-
tion of AKT and ERK signaling by Riluzole is affected by these
feedback loops, we repeated the western analysis in cells
with an extended Riluzole treatment. When C8161 cells were
treated with 25 mM Riluzole for 18 hours there was still a
dramatic decrease in both pAKTT308 and pAKTS473 when
compared with DMSO-treated cells (Figure 3c). However
AKT and ERK-1/2 phosphorylation levels returned to un-
treated levels in HT144 and SKMEL2 cell treated with
Riluzole for 18 hours. The reduced phosphorylation of ERK-
1/2 also returned to steady-state levels in all the cell lines
treated with Riluzole at the 18-hour time point. For
UACC930 cells induction of AKT and ERK-1/2 phosphoryla-
tion observed in the 8-hour treatment was no longer visible in
the 18-hour treated cells. These data suggest that over time
feedback mechanisms in these cells can reduce the AKT and
ERK inhibition induced by Riluzole. Additionally presence of
a BRAFV600E mutation and PTEN truncation in HT144 and
NRASQ61R mutation in SKMEL2 cells may attenuate the
inhibition induced by Riluzole.
One of the issues of using cancer cell lines for the study of
pharmacological agents is that cell lines potentially may have
acquired mutations that were not originally present in the
tumor of origin. Additionally, cell lines do not replicate the
three-dimensional microenvironment present in tumors. This
is likely why successful inhibition in a cell culture system
often does not translate into the clinic. To investigate this
issue, we tested the ability of Riluzole and BAY 36-7620 to
inhibit the growth of melanoma tumors. Fresh melanoma
tumors can usually be grown in a simple explant assay where
the tumors are placed on a tissue culture dish and outgrowth
of cells from the tumor can be observed. The issue with this
method is that normal cells from residual stromal tissue can
also grow under these conditions. To circumvent this issue
we performed our fresh tumor growth assays using an
organotypic culture method. In this procedure the tumor
tissue is implanted on a 74-mm nylon mesh and growth of
cells into the interstitial spaces of the mesh is observed.
Tumor cells can grow into the interstitial spaces of the mesh,
but normal cells cannot due to a lack of anchorage. The
tumor samples were carefully dissected to remove any
stromal tissue and then implanted onto Corning Netwells
that contain a 74-mm nylon mesh and cultured in the
presence of Riluzole, BAY 36-7620, U0126, and a vehicle
solvent (DMSO). In vehicle-treated tumors, cells readily grew
out from the implanted tumor mass into the interstitial spaces
of the mesh (Figure 4). Treatment with 25 mM Riluzole
completely abrogated this growth. Use of 50mM BAY 36-
7620 also produced the same effect. U0126 did not prevent
the outgrowth of cells from the tumor mass at all. All three
tumor samples were shown to be GRM1 expressers by
immunohistochemical staining (data not shown). When the
treatments were repeated using samples of a normal mole we
observed that although Riluzole and BAY 36-7620 did
decrease the growth of cells into the interstitial spaces of
the mesh, it was not to the degree shown in the tumor
samples.
DISCUSSION
Our group has established that the majority of human
melanomas ectopically express GRM1 and that this cell-
surface receptor is functional with its activation resulting in
activation of the MAPK and PI3K/AKT pathways (Marin et al.,
2006; Namkoong et al., 2007; Shin et al., 2008a, b). We have
now also shown that inhibition of GRM1 activation results in
a decrease in melanoma cell migration and invasion, and
decrease in proliferation in vitro, phenotypic characteristics
that have been attributed to MAPK and PI3K/AKT signaling in
human melanoma (Hendrix et al., 2003; Hess et al., 2005).
Lack of effect of Riluzole and BAY 36-7620 on the GRM1-
negative UACC930 cell line shows these agents likely
function at least in part by suppressing signaling through this
receptor. We have also shown that treatment of melanoma
cells cultured in soft agar with Riluzole or BAY 36-7620
suppresses colony formation and decreases colony size in
GRM1þ cell lines. Finally, we have now shown that we can
suppress the proliferation of fresh melanoma samples by
addition of Riluzole or BAY 36-7620 to the culture media in
an organotypic culture model. These findings suggest that
GRM1 is a potential therapeutic target for treatment of
patients with melanoma and that suppression of MAPK and
PI3K/AKT signaling is likely responsible for at least some of
the effects seen when the GRM1-signaling pathway is
inhibited. These results will be important as we design
Riluzole-based combination therapies that complement the
effects of Riluzole on human melanoma cells.
Riluzole is the only FDA-appoved GRM1-blocking agent
and is used to slow the progression of disease in patients with
amyotropic lateral sclerosis (Miller et al., 2003; Gordon,
2005). Riluzole is a potent inhibitor of glutamate release from
neurons, likely disrupting the autocrine loops responsible for
the excitotoxicity thought to be the cause of amyotrophic
lateral sclerosis, but the exact mechanism of Riluzole’s action
is unknown (Noh et al., 2000; Miller, 2003; Miller et al.,
2003; Swash, 2005). We were interested in Riluzole because
it has a well-characterized toxicity profile (Le Liboux et al.,
1999) and could be quickly introduced into clinical trials if it
was shown effective in inhibiting melanoma proliferation
in vitro and in murine models of human melanoma. We
have previously published our pre-clinical studies of Riluzole
and we have now reported the results of a phase-0
clinical trial of oral Riluzole in patients with advanced
melanoma (Yip et al., 2009). We have shown that Riluzole
inhibits signaling through the MAPK and PI3K/AKT pathways
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in post-treatment tumor samples as compared with pre-
treatment samples in a significant proportion of the
patients receiving the drug. Surprisingly, we also found that
34% of patients on this trial had significant clinical responses
to the administration of just 2 weeks of oral Riluzole.
We have begun a phase-II therapeutic trial of Riluzole in
patients with advanced melanoma and we have continued to
explore the effects of this agent on melanoma cells. This
study shows that one effect Riluzole has on human
melanoma cells is to inhibit migration and invasion of
melanoma cells, and to inhibit melanoma proliferation
in vitro. It is less clear if inhibition of signaling through
GRM1 has an effect on the release of uPA by these cells, with
only a modest change in uPA release detected in our pre-
clinical experiments.
It is also important to note that there are eight metabo-
tropic glutamate receptors that have been described in the
CNS of mammals (Chong et al., 2003; Fagni et al., 2004;
Simeone et al., 2004). All of these GRM receptors use
glutamate as their natural ligand and inhibition of glutamate
release by agents such as Riluzole could conceivably affect
signaling through all eight of these receptors if present on
melanoma cells. We have checked for the presence of
GRM2–8 in melanoma cell lines and tumor samples
(unpublished data) and found GRM6 and GRM8 to be
expressed by the majority of the cell lines and tissue
examined. This includes UACC930 cells that we use for
controls in these experiments because this cell line does not
express GRM1. We are continuing to examine the role of the
other GRMs in melanoma pathogenesis and progression but it
does appear that GRM1 is necessary for much of the effects
seen with Riluzole and BAY 36-7620 treatment given the lack
of effects on UACC930 cells.
It is also significant that we found that Riluzole can inhibit
signaling through the MAPK and PI3K/AKT pathways in
melanoma cells in vitro when the cells are treated for 8 hours
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Figure 4. Riluzole and BAY 36-7620 inhibit the growth of fresh melanoma tumors. Freshly harvested melanoma tissues were used in an organotypic growth
assay as indicated in section Materials and Methods. Twenty-four hours after implanting the tumor tissue on the mesh the samples were treated with 25 mM
Riluzole, 50mM BAY 36-7620, 10mM U0126, or vehicle solvent (DMSO). Medium was replenished every 48 hours. Cells were allowed to grow out from the
tumor sample for a period of 14 days after which photomicrographs were taken. The original tumor sample is on the left of each photomicrograph.
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but that this is effect is reversed by 18 hours of treatment.
Whereas reactivation of the MAPK pathway was observed in
all the GRM1þ cell lines, re-phosphorylation of AKT was
only observed in the HT144 and SKMEL2 melanoma cell
lines harboring activating mutations in B-RAF and N-RAS,
respectively. It should be noted that HT144 with a PTEN
truncation has hyper-activation of the PI3K pathway. In
C8161 cells, which are wild type for PTEN, re-phosphoryla-
tion of AKT was not observed. Potentially, constitutive
activation of the PI3K pathway in HT144, through PTEN
inactivation, and SKMEL2, through N-RAS activation, is
responsible for transient nature of the inhibitory effects of
Riluzole in these cell lines. It is also possible that feedback
loops activated by inhibition of these pathways by Riluzole
result in re-phosphorylation of AKT and ERK, reactivating
these pathways. We are currently investigating both possibi-
lities to gain further insight into the inhibitory effects of
Riluzole.
In our anchorage-independent growth assays Riluzole
showed less inhibition in the HT144 and SKMEL2 lines than
in the C8161 cell line. There was also re-phosphorylation of
AKT in these lines but not in C8161. This implies that
reactivation of the PI3K-signaling pathway may be respon-
sible for the decreased efficacy of Riluzole in these lines. If
this is the case, expression of a constitutively active PI3K
p110 (cap110) in C8161 cell would attenuate the inhibitory
effects of Riluzole. Alternatively direct inhibition of the
signaling molecules of the PI3K pathway in HT144 and
SKMEL2 lines may increase the efficacy of Riluzole in these
cells. Investigations into expression of cap110 in C8161 and
combinations of Riluzole with inhibitors to PI3K pathway-
signaling molecules in pre-clinical experiments are currently
ongoing.
It is important to note that despite reactivation of AKT and
ERK signaling in HT144 and SKMEL2 cells there was still
significant decreases in both invasion and colony formation.
This suggests that while both ERK and PI3K signaling
contribute to melanocytic transformation, other factors are
involved. GRM1 is primarily coupled to the Gq family of
proteins and stimulates phosphoinositide hydrolysis where
phospholipase-Cb converts PI into inositol triphosphate-3 and
diacylglycerol. Inositol triphosphate-3 induces the release of
intracellular calcium and diacylglycerol activates protein
kinase-C. Protein kinase-C activates multiple downstream
effectors, including phospholipase-A2, phospholipase-D, and
ERK. Gs proteins have also been shown to be coupled to
GRM1, resulting in the activation adenylate cyclase and
protein kinase-A. GRM1 is also known to signal through the
HOMER family of scaffolding proteins to induce PI3K
activity. The contribution of GRM1 induction of these other
pathways to the development of melanoma and the effect of
Riluzole on these pathways is currently unknown and need to
be further investigated.
Our results with the GRM1 cell line, UACC930, were
somewhat mixed in that Riluzole had essentially no effect on
colony formation but appeared to induce increase invasion.
Additionally there appeared to be transient increase in AKT
and ERK-1/2 phosphorylation. Our UACC930 colony assays
required 21 days for growth of colonies, whereas the invasion
assays were completed in 48 hours. Given the transient
nature of the induction of AKT and ERK-1/2 phosphorylation
it is likely that the nature of the experiments had an important
role in the outcome. In the short invasion assays the initial
induction of PI3K and MAPK signaling may have caused an
increase in invasion. In the colony assay, due to the longer
duration, the initial induction of AKT and ERK-1/2 phosphory-
lation does not affect the formation of colonies significantly
as by 18 hours phosphorylation has returned to steady-state
levels. Given that the goal of this study is to evaluate the
therapeutic potential of Riluzole, it is important that any
adverse outcomes be investigated. It is crucial to repeat these
experiments in other GRM1 cell lines with differential PI3K
and MAPK activation states. We have only been able to
locate one other GRM1 melanoma cell line; however this
cell line is not suitable for our experiments as they grow
extremely slowly and do not form colonies in soft agar. We
will continue in our attempts to locate GRM1 cell lines as
well as explore the possibility of using primary melanoma
cultures to resolve the issue.
The western blot experiments were performed in a
standard monolayer culture environment and so might not
recapitulate what happens in vivo. Indeed, in the patients on
our phase-0 trial of Riluzole we found profound decrease in
AKTT308 and pERK-1/2 in post-treatment tumors as compared
with that in pre-treatment tumors in patients who clinically
responded to Riluzole administration. We are currently
adapting an anchorage-independent culture system for
recovery of colonies to use in biochemical analysis to test
whether this phenomenon occurs when melanoma cells are
grown in anchorage-independent colonies. If we find that an
anchorage-independent culture system better mimics the
observed in vivo effects of Riluzole on melanoma cells we
will use this system to screen future compounds and
combination therapies before in vivo experiments. It is also
possible that feedback reactivation of the PI3K/AKT or
MAPK pathways could result in resistance to Riluzole-based
therapies and we are currently examining therapies that
combine Riluzole and other agents that affect signaling
through the MAPK and PI3K/AKT pathways. We are
also continuing our studies into GRM1 signaling in
melanoma and the mechanism of action or Riluzole
by investigating other pathways stimulated by GRM1 or
inhibited by Riluzole.
Our group first described the ectopic expression of GRM1
in human cancer and that these receptors function and are
likely important in the melanomagenesis. We have translated
these findings into the clinic in the form of phase-0 and
phase-II trials of the glutamate signaling-inhibitory agent
Riluzole in patients with advanced melanoma and have
now taken our clinical and pre-clinical findings back to
the laboratory. We now report that the inhibition of
signaling through the MAPK and PI3K/AKT pathways seen
in pre-clinical and clinical studies does indeed translate
into decreased migration, invasion, and proliferation in
melanoma cell lines and tissues that express GRM1, but not
in those that do not. We will use these new data to begin to
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design combinatorial therapies that target GRM1 signaling
and signaling through other pathways known to be important
for the pathogenesis of melanoma.
MATERIALS AND METHODS
Reagents
Riluzole, BAY 36-7620, and U0126 were purchased from Tocris
Biosciences (cat. no. s 0768, 2501, and 1144, respectively). Anti-
phospho-ERK (no. 9010), total ERK (no. 9102), phospho-AKT473 (no.
4051), phospho-AKT308 (no. 2965), and total AKT (no. 9272) were
purchased from Cell Signaling Technologies (Danvers, MA). Goat
anti-rabbit IgG-HRP was purchased from Sigma, St Louis, MO (A0545).
Cell culture
A2058, A375, and C8161 melanoma cell lines were grown in
Dulbecco’s Modification of Eagle’s Media (D-MEM) (Mediatech,
10-013-CV) containing 10% fetal bovine serum (FBS). SKMEL2,
SKMEL5, SKMEL28, and SKMEL31 melanoma cell lines were grown
in MEM (ATCC, 30-2003) containing 10% FBS. HT144 cells were
grown in McCoys5A (Invitrogen, Carlsbad, CA, catalog no. 16600)
containing 10% FBS and UACC930 cell were grown in RPMI-1640
(Invitrogen, 11875) containing 10% FBS. All cell lines were
maintained in a humidified incubator at 37 1C with 5% CO2.
Invasion assays
Invasion assays were performed using a standard Boyden chamber
according to established protocols (Cheng et al., 2007). Briefly
8.0mm cell culture inserts in their 24-well companion plates (BD-
Falcon, Franklin Lakes, NJ, 3097 and 3504, respectively) were
coated with 100ml of 0.5mgml1 Matrigel in 0.1% BSA DMEM and
allowed to gel for 2 hours at 37 1C. The gel was then hydrated for
30minutes with 400 ml 0.1% BSA in DMEM. The medium was then
aspirated carefully and 2 104–1 105 cells in 500ml of 0.1% BSA
DMEM containing the inhibitors were added to the insert and placed
in a 37 1C incubator for 2 hours. A 750-ml volume of 10% fetal calf
serum DMEM containing the inhibitors was added to the companion
plate to act as a chemoattractant and cells were allowed to invade
18–48hours. For 48-hour invasion assays fluid renewal of both the
upper and lower chambers occurred at the 24-hour mark. Cells in
the chamber were then removed using cotton swabs and the invaded
cells were fixed and stained with a 0.1% crystal violet, 1% formalin,
and 20% ethanol solution for 30minutes. The inserts were then
washed with phosphate-buffered saline 2 and photomicrographs
of three representative fields taken. Using Image J invasion
levels were determined by analyzing the surface area occupied by
the cells in each of the representative photomicrographs and
averaging. Invasion activity was expressed as levels relative to
vehicle control and histograms represent the average of three
independent experiments.
Soft agar colony assays
Cells were suspended in 600ml of RPMI-1640 containing 10% FBS,
10% MCDB 153, and 0.35% agar. This is then overlayed onto 1ml
of RPMI-1640 containing 10% FBS, 10% MCDB 153, and 0.75%
agar in one well of a 12-well tissue culture plate. The pharmaco-
logical agents were incorporated into both the layers. Colonies were
allowed to form for 14–21 days at which point three representative
photomicrographs were taken.
Colony numbers and sizes were analyzed using the Image J
software. Briefly, photomicrographs were analyzed to determine the
number of colonies and the pixel area of each colony. The number
of colonies from three representative photomicrographs was totaled
and colony-forming potential relative to DMSO-treated cells was
determined. Colony pixel areas for all treatments for each cell line
were used to determine the minimum, maximum, and standard
deviation values. These values were used to determine a colony size
range, which was divided into 16 sub-ranges for sorting of the
colony sizes. The numbers of colonies for each sub-range were
plotted for a size distribution curve. The histograms represent the
average of three independent experiments.
Protein extraction and western blotting
Total cell lysates were prepared using a modified NP-40 extraction
buffer (25mM Tris–HCl (pH 7.4), 150mm NaCl, 1mM EDTA, 1mM
DTT, 0.5% NP-40, 10% glycerol, complete protease inhibitor tablets
(Roche, Indianapolis, IN, catalog no. 1836153), 1mM phenyl methyl
sulfonyl fluoride, 50mM b-glycerol phosphate, 10mM p-nitrophenyl
phosphate, 2.5mM sodium pyrophosphate, 100 nM okadaic acid,
10mM sodium fluoride, 1mM sodium orthovanadate, and 10 mM
phenylarsine oxide). Protein amounts were determined by Bradford
assay and routinely 10 mg of total cell lysates was resolved on 10%
SDS-PAGE gels, and proteins transferred onto 0.2 mm polyvinylidene
difluoride membrane. The membrane was then blocked and probed
with antibodies according to a standard western blotting protocol.
After primary antibody binding, the membranes were incubated with
the corresponding horseradish peroxidase (HRP)-conjugated sec-
ondary antibody. Proteins were detected by enhanced chemilumi-
nescence (GE Healthcare, Piscataway, NJ, catalog no. RPN2132)
and exposure to X-ray film.
uPA activity assay and gelatin zymography
uPA activity assays were performed according to the manufacturer’s
suggested protocol (Chemicon, Billerica, MA, catalog no. ECM600).
A 20-mg weight of total cell lysate was used to perform the assay. The
assays were performed in duplicate and values were averaged.
Results are from three independent experiments. Zymogram gels
were purchased from Invitrogen (EC61752) and used according to
the manufacturer’s protocol.
Organotypic tumor culture
Freshly harvested melanoma tumor samples were obtained through
the Tissue Retrieval Service, a shared resource core of the Cancer
Institute of New Jersey, in an IRB-approved and HIPPA-compliant
manner. The samples were first carefully dissected to remove any
non-tumor tissue. The tumor samples were then sliced using stacked
razor blades to obtain slices of uniform thickness (B0.5mm). From
these slices 2mm punches of tissue were taken and treated with
dispase for 1minute. The samples were then implanted into Corning/
Costar Netwells containing a 74mm nylon mesh in 12-well plates. A
1-ml volume of 10% FBS RPMI-1640 was added to each well and
the plates incubated at 37 1C for 24 hours. The medium was then
replaced with 1ml of 10% RPMI-1640 containing either DMSO,
Riluzole (25mm), BAY 36-7620 (50 mM), or U0126 (10 mM) and the
plates incubated for 7–14 days. Fluid renewal occurred every 2 days.
At the initial implantation and at each fluid renewal 20 ml of medium
was directly added to the tumor tissue to keep it sufficiently
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humidified. Phase-contrast photomicrographs were taken at the end
of the assay.
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